During the last session, ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s traded shares were 0.68 million, with the beta value of the company hitting 0.90. At the end of the trading day, the stock’s price was $14.52, reflecting an intraday gain of 4.39% or $0.61. The 52-week high for the SPRY share is $16.50, that puts it down -13.64 from that peak though still a striking 76.93% gain since the share price plummeted to a 52-week low of $3.35. The company’s market capitalization is $1.41B, and the average intraday trading volume over the past 10 days was 0.79 million shares, and the average trade volume was 1.09 million shares over the past three months.
ARS Pharmaceuticals Inc (SPRY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SPRY has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
ARS Pharmaceuticals Inc (SPRY) registered a 4.39% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.39% in intraday trading to $14.52, hitting a weekly high. The stock’s 5-day price performance is 2.33%, and it has moved by 14.96% in 30 days. Based on these gigs, the overall price performance for the year is 265.28%. The short interest in ARS Pharmaceuticals Inc (NASDAQ:SPRY) is 11.1 million shares and it means that shorts have 10.96 day(s) to cover.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 34.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $30 respectively. As a result, SPRY is trading at a discount of -106.61% off the target high and -23.97% off the low.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
Statistics show that ARS Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. ARS Pharmaceuticals Inc (SPRY) shares have gone up 60.98% during the last six months, with a year-to-date growth rate less than the industry average at -15.79% against 19.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -1.44%. While earnings are projected to return -11.21% in 2024.
SPRY Dividends
ARS Pharmaceuticals Inc is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
ARS Pharmaceuticals Inc insiders own 23.21% of total outstanding shares while institutional holders control 65.31%, with the float percentage being 85.06%.
